Get the Stockscreener App
0.2367
1.78%
-0.0043
After Hours:
.23
-0.0067
-2.83%
Mainz Biomed N V stock is traded at $0.2367, with a volume of 1.10M.
It is down -1.78% in the last 24 hours and down -2.15% over the past month.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
See More
Previous Close:
$0.241
Open:
$0.2394
24h Volume:
1.10M
Relative Volume:
0.53
Market Cap:
$6.14M
Revenue:
$895.50K
Net Income/Loss:
$-26.30M
P/E Ratio:
-0.1239
EPS:
-1.91
Net Cash Flow:
$-23.84M
1W Performance:
-12.33%
1M Performance:
-2.15%
6M Performance:
-67.87%
1Y Performance:
-90.38%
1-Day Range:
$0.2315
$0.2469
1-Week Range:
$0.2122
$0.273
52-Week Range:
$0.1852
$3.3923
Mainz Biomed N V Stock (MYNZ) Company Profile
Name
Mainz Biomed N V
Sector
Industry
Phone
-
Address
-
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-21-22 | Initiated | H.C. Wainwright | Buy |
Mainz Biomed N V Stock (MYNZ) Latest News
Is Now The Time To Buy Mainz Biomed N.V. (NASDAQ: MYNZ) Stock? - Stocks Register
Mainz Biomed’s half-yearly revenue increases 4% YoY - Medical Buyer
Mainz Biomed restructured operations, implemented cost reductions - Yahoo Finance
Mainz Biomed reports revenue growth and reduced losses By Investing.com - Investing.com South Africa
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed N : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Form 6 K - Marketscreener.com
Financial Metrics Unveiled: Mainz Biomed N.V. (MYNZ)’s Key Ratios in the Spotlight - The Dwinnex
Mainz Biomed N.V.: Navigating Market Fluctuations with a 5.69M Market Cap - The InvestChronicle
Stocks of Mainz Biomed N.V. (MYNZ) are poised to climb above their peers - SETE News
Evaluating MYNZ’s financial ratios for a profitable investment - US Post News
Investors’ Faith in Mainz Biomed N.V. (MYNZ) could reap rewards if they hold on for the long haul - US Post News
Mainz Biomed Secures Additional $1.5M Funding - Yahoo Finance
Mainz Biomed N.V. [MYNZ] Stock trading around $0.38 per share: What’s Next? - The DBT News
Mainz Biomed N : Material Definitive Agreement Form 6 K - Marketscreener.com
Views of Wall Street’s Leading Experts on Mainz Biomed N.V. - SETE News
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version - GlobeNewswire
Mainz Biomed N.V.: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Understanding MYNZ’s book value per share for better investment insights - US Post News
Market Watch: Mainz Biomed N.V. (MYNZ)’s Noteworthy Drop, Closing at 0.24 - The Dwinnex
Mainz Biomed Executes Convertible Note Agreement - TipRanks
Mainz Biomed plans FDA trial for cancer test in 2025 - Investing.com India
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - GlobeNewswire
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials - The Bakersfield Californian
Taking on analysts’ expectations and winning: Mainz Biomed N.V. (MYNZ) - SETE News
Mainz Biomed N.V. (MYNZ) Stock: A Year of Decreases and Increases - The InvestChronicle
Technical analysis of Mainz Biomed N.V. (MYNZ) stock chart patterns - US Post News
Market Highlights: Mainz Biomed N.V. (MYNZ) Ends on a High Note at 0.25 - The Dwinnex
What is Mainz Biomed N.V. (MYNZ) Stock Return on Shareholders’ Capital? - SETE News
Is Mainz Biomed N.V. (MYNZ) a good investment opportunity? - US Post News
Market Recap: Mainz Biomed N.V. (MYNZ)’s Negative Momentum, Closing at 0.24 - The Dwinnex
Mainz Biomed (NASDAQ:MYNZ) Stock Quotes, Forecast and News Summary - Benzinga
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - GlobeNewswire
Financial Fitness Check: Examining Mainz Biomed N.V. (MYNZ)’s Key Ratios - The Dwinnex
It makes sense and dollars to buy Mainz Biomed N.V. (MYNZ) stock - SETE News
Mainz Biomed N.V. (MYNZ) deserves deeper analysis - US Post News
MYNZ Stock on the Rise: A Promising Investment - The InvestChronicle
Mainz Biomed to unveil breakthrough early cancer detection study results at DDW 2024 - MSN
Quarterly Snapshot: Quick and Current Ratios for Mainz Biomed N.V. (MYNZ) - The Dwinnex
Mainz Biomed stock plunges to 52-week low of $0.3 amid market challenges - Investing.com
Behind Mainz Biomed N.V.’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Taking the lead: Mainz Biomed N.V. (MYNZ) - SETE News
MYNZ’s valuation metrics: A comprehensive analysis - US Post News
Insider’s View: Deciphering Mainz Biomed N.V. (MYNZ)’s Financial Health Through Ratios - The Dwinnex
Mainz Biomed and Liquid Biosciences Collaborate on Innovative Pancreatic Cancer Detection Tool - Vancity Buzz
An analyst sees good growth prospects for Mainz Biomed N.V. (MYNZ) - SETE News
Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool | FinancialContent Business Page - Financial Content
Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fi - News Channel Nebraska
Mainz Biomed N.V. (MYNZ) Stock: From Low to High in 52 Weeks - The InvestChronicle
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert - Yahoo Finance UK
Mainz Biomed (NASDAQ:MYNZ) Stock Price Up 11.1% - Defense World
Mainz Biomed N.V. (MYNZ) deserves closer scrutiny - US Post News
Mainz Biomed N V Stock (MYNZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.48%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):